Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report

Lung Cancer. 2006 Feb;51(2):257-9. doi: 10.1016/j.lungcan.2005.10.007. Epub 2006 Jan 18.


A 65-year-old male with 40-pack year smoking history presented with exertional dyspnea and was subsequently diagnosed with bronchiolo-alveolar carcinoma (BAC). He did not respond to first line therapy with geftinib, but he achieved disease stabilization with gemcitabine and carboplatin for 4 months before developing symptomatic worsening requiring oxygen supplementation. He responded dramatically to bortezomib with rapid symptom improvement. The follow-up computerized tomography revealed partial response that was maintained for 11 months. Based on observations like this and those seen in phase I studies with bortezomib, this agent is being studied now in patients with bronchio-alevolar cancer.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma, Bronchiolo-Alveolar / diagnostic imaging
  • Adenocarcinoma, Bronchiolo-Alveolar / drug therapy*
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Humans
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / drug therapy*
  • Male
  • Pyrazines / therapeutic use*
  • Tomography, X-Ray Computed


  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib